New BTK blocker aims to outsmart drug resistance in elderly CLL patients
Disease control
Recruiting now
This phase 2 trial tests a drug called pirtobrutinib in people aged 75 and older with untreated chronic lymphocytic leukemia (CLL). Pirtobrutinib is a next-generation BTK inhibitor designed to block cancer growth signals, potentially working even when other similar drugs stop bei…
Phase: PHASE2 • Sponsor: Jennifer Woyach • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC